Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in clinical-stage drug developer Syntara to 19.24%, fresh off the commencement of a Phase 2a clinical study that has the potential to become a new treatment for patients diagnosed with myelofibrosis (bone marrow cancer). The combination
Read More
Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where
Read More
Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis (ASX: PXS) has quickly jumped forward in the commercialisation process having been cleared by the US Food and Drug Administration (FDA) to commence a combination arm of the trial. The clearance of the amended trial
Read More
In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis. The data revealed 60% of trial patients experienced a significant improvement in
Read More
A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to access a new treatment which has already shown to be effective in a small group of patients undergoing treatment of PXS-5505 in Phase 2 clinical trials. Myelofibrosis is a rare cancer of the bone marrow
Read More
There is an urgent need for better treatment for myelodysplastic syndrome (MDS), a type of blood cancer, and new research published in prestigious scientific journal Nature Communications suggests a breakthrough could be coming. Researchers at the University of Heidelberg in Germany have reported results claimed to be “the best we have ever observed in our
Read More